机译:基于蛋白质的多重分析的分析验证:NCI-FDA机构间肿瘤学工作组分子诊断研讨会报告
Henry Rodriguez,1* ivana Teak,1 Mehdi Mesri,1 Steven A. Carr,1 Daniel C. Liebler,1 Susan J. Fisher,1 Paul Tempst,1 Tara Hiltke,1 Larry G. Kessler,1 Christopher R. Kinsinger,1 Reena Philip,1 David F. Ransohoff,1 Steven J. Skates,1 Fred E. Regnier,1 N. Leigh Anderson,1 and Elizabeth Mansfield,1 on behalf of the Workshop Participants[dagger]1 National Cancer Institute-Food and Drug Administration Interagency Oncology Task Force on Molecular Diagnostics.* Address correspondence to this author at: Center for Strategic Scientific Initiatives, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892. E-mail: rodriguezh@mail.nih.gov.[dagger] See Appendix for complete list of workshop participants.Received September 17, 2009, accepted November 22, 2009.Previously published online at DOI: 10.1373/clinchem.2009.136416Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data, (b) drafting or revising the article for intellectual content, and (c) final approval of the published article.Authors' Disclosures of Potential Conflicts of Interest: Upon manuscript submission, all authors completed the Disclosures of Potential Conflict of Interest form. Potential conflicts of interest:Employment or Leadership: P. Tempst, Memorial Sloan-Kettering Cancer Center, F.E. Regnier, Purdue University and Quadraspec.Consultant or Advisory Role: P. Tempst, Yale University Medical School, F.E. Regnier, Quadraspec.Stock Ownership: F.E. Regnier, BG Medicine, Quadraspec, and Predictive Physiology and Medicine.Honoraria: None declared.Research Funding: D.C. Liebler, NCI, P. Tempst, NCI/NIH, F.E. Regnier, NCI.Expert Testimony: F.E. Regnier, Pharmacia versus Genentech.Other Remuneration: S. Skates, Teva Inc. (for travel to a scientific conference in Tel Aviv), F.E. Regnier, Gesellschaft Deutscher Chemiker (GDCh) (for travel to, and other expenses related to attending, HPLC 2009 in Dresden).Role of Sponsor: The funding organizations played a direct role in the review and interpretation of data and the preparation or approval of manuscript.,;
机译:基于蛋白质的多重测定的分析验证:NCI-FDA机构间肿瘤学工作组关于分子诊断的研讨会报告。
机译:基于蛋白质的多重分析的分析验证:NCI-FDA机构间肿瘤学工作组分子诊断研讨会报告
机译:BCR-ABL1在国际范围内的监测使用了经过临床和分析验证的多重分析,该分析直接符合WHO的主要标准,并且统一了报告格式
机译:细胞因子测量简易-Plex ella平台多重测定的分析验证
机译:布鲁氏菌病诊断分析方法的验证和分子流行病学工具的开发。
机译:多种生物标记物分析将结直肠癌分为分子亚型的分析验证
机译:基于蛋白质的多重测定分析验证:NCI-FDA间歇性肿瘤专员对分子诊断的研讨会报告
机译:从外周血细胞中分离RNa:通过微阵列和动力学RT-pCR检测分子诊断的验证研究 - 在航空航天医学中的应用